Drug intelligence / Profile preview

ucb4019

Development stage
Preclinical
Lead developer
UCB
Modality
Small Molecules
Administration
Subcutaneous
01

Overview

**UCB4019** is an investigational pharmaceutical drug developed by UCB. It is administered via subcutaneous injection and is currently being evaluated primarily for its safety and tolerability in healthy volunteers, with potential indications in several autoimmune diseases. The mechanism of action has not been formally disclosed; available sources suggest it may be intended for the treatment of immune-mediated diseases such as myasthenia gravis, pemphigus vulgaris, and neuromyelitis optica, but the exact molecular target and pathway are not yet published. - First-in-human clinical studies are ongoing, with a primary focus on single ascending dose trials to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD)[1][3][5][7]. - It is categorized as a small molecule drug[7].

Brand names
UCB4019UCB-4019UCB 4019
Other names
UCB4019UCB-4019UCB 4019

Beyond the preview

Go deeper on ucb4019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ucb4019.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call